All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?
During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Jacob Laubach,...
Updated efficacy and safety analysis from the phase III CANDOR study
On December 3, 2021, Saad Usmani and colleagues published the updated safety and efficacy analysis of the phase III CANDOR study (NCT03158688) in Lancet Oncology.
"The MM Hub is the ideal platform for the latest news about myeloma. You will find information about the most recent data, and also personal experiences from experts managing myeloma patients in their clinical practice."